Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): A randomized, phase 3 clinical trial

Authors

Jonathan W Friedberg, University of Rochester
Brad S Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

eClinicalMedicine

Publication Date

12-1-2024

Volume

78

First Page

102959

Document Type

Open Access Publication

DOI

10.1016/j.eclinm.2024.102959

Rights and Permissions

Friedberg JW, Brady MT, Strawderman M, Kahl BS, Lossos IS, Cohen JB, Reagan PM, Casulo C, Averill BL, Baran A, Sutamtewagul G, Barr PM, Leonard JP, Ashton JM, Strang JG, Vega F, Peterson DR, Nastoupil LJ. Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. EClinicalMedicine. 2024 Nov 27;78:102959. doi: 10.1016/j.eclinm.2024.102959. © 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Friedberg, Jonathan W; Kahl, Brad S; and et al., "Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): A randomized, phase 3 clinical trial." eClinicalMedicine. 78, 102959 (2024).
https://digitalcommons.wustl.edu/oa_4/5191

Additional Links

Supplemental material is available for this article at publisher site.